Finding a place for tumor-specific T cells in targeted cancer therapy.
A goal in cancer therapeutics is to develop targeted modalities that distinguish malignant from normal cells. T cells can discriminate diseased cells based on subtle alterations in peptides displayed in association with MHC molecules at the cell surface. Recent success using the adoptive transfer of tumor-specific T cells has fueled optimism that this approach may find a place as a targeted therapy for some human cancers.
Riddell
Stanley R
SR
Program in Immunology, D3-110, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109, USA. sriddell@fhcrc.org
D000938:Antigen-Presenting Cells / Q000276:immunology; D049109:Cell Proliferation; D002470:Cell Survival / Q000276:immunology; D006649:Histocompatibility Antigens / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000276:immunology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology / Q000637:transplantation*; D016131:Lymphocyte Subsets / Q000276:immunology / Q000637:transplantation*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000637:transplantation*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation*
D006649:Histocompatibility Antigens; D007376:Interleukin-2